

# Bijlage Zoekverantwoording

## Onderzoeksvraag 2 (module Behandeling van maligne hypercalciëmie)

Wat is het effect van bisfosfonaten, calcitonine, denosumab, corticosteroiden, cinacalcet, diuretica, galliumnitraat en hyperhydratie op maligne hypercalciëmie in de palliatieve fase?

### PICO

P	Patiënten met kanker en hypercalciëmie in de palliatieve fase
I	Bisfosfonaten, calcitonine, denosumab, corticosteroiden, cinacalcet, diuretica (furosemide), galliumnitraat, hyperhydratie
C	Interventies onderling, andere behandeling, geen behandeling
O	Cruciaal: hoogte van het serumcalcium, duur van het effect, bijwerkingen Belangrijk: kwaliteit van leven, symptomen (misselijkheid, sufheid, obstipatie)

### Zoekstrategie

Ovid MEDLINE(R): 1946 to December 27, 2022

- 1 (cancer\* or carcinoma\* or adenocarcinoma\* or hepatocarcinoma\* or carcinosarcoma\* or sarcoma\* or histiocytoma\* or fibrosarcoma\* or osteosarcoma\* or chondrosarcoma\* or lymphosarcoma\* or rhabdomyosarcoma\* or leuk?emi\* or erythroleukem\* or erythroleukaem\* or lymphoma\* or melanoma\* or hodgkin\* or "multiple myeloma" or mesothelioma\* or neoplas\* or malignan\* or metastas\* or carcinoid\* or neuroblastoma\* or (Mycosis adj Fungoid?s) or (Sezary adj Syndrome) or Retinoblastoma\* or pheochromocytoma\* or nephroblastoma\* or choriocarcinoma\* or (Pleuropulmonary adj Blastoma?) or glioblastoma\* or glioma\* or astrocytoma\* or ependymoma\* or medulloblastoma\* or meningioma\* or craniopharyngioma\* or myelodysplastic or myeloproliferative or macroglobulinemi\* or macroglobulinaemi\* or pineoblastoma\* or oncol\* or cyst or tumo?r\*).mp. or exp Neoplasm/ (4780599)
- 2 Calcinosis/ or hypercalcemia/ or (calcinosis or hypercalcemi\*).mp. (60179)
- 3 (HHM or LOH).mp. (7057)
- 4 1 and 2 (19981)
- 5 3 or 4 (26826)
- 6 randomized controlled trial.pt. (581950)
- 7 controlled clinical trial.pt. (95108)
- 8 randomized.ab. (513566)
- 9 placebo.ab. (214932)
- 10 clinical trials as topic.sh. (201502)
- 11 randomly.ab. (337367)
- 12 trial.ti. (242253)
- 13 6 or 7 or 8 or 9 or 10 or 11 or 12 (1347657)
- 14 exp animals/ not humans.sh. (5083790)
- 15 13 not 14 (1228519)
- 16 meta-analysis.mp.pt. or review.pt. or search:.tw. (3172194)
- 17 15 or 16 (4187278)
- 18 5 and 17 (4278)
- 19 Palliative Care/ (61469)
- 20 "Hospice and Palliative Care Nursing"/ (2010)
- 21 exp Palliative Medicine/ (486)
- 22 exp Terminal Care/ (56077)
- 23 Terminally Ill/ (6790)
- 24 palliat\*.mp. (99853)
- 25 ((terminal\* or advance\*) adj6 (care or caring or ill\* or sick\* or stage\*)).mp. (126578)
- 26 (terminal-stage\* or (terminal adj1 stage\*) or dying or (close adj6 death)).mp. (39909)
- 27 (end adj3 life).mp. (27359)
- 28 hospice\*.mp. (18907)
- 29 ((end-stage\* or (end adj1 stage\*)) adj6 (disease\* or ill\* or care or caring)).mp. (55575)

30 ((incurable or advanced) adj6 (ill\* or disease\*)).mp. (58795)  
 31 (reduced adj1 life adj2 expectanc\*).mp. (925)  
 32 or/19-31 (351171)  
 33 18 and 32 (241)  
 34 exp Diphosphonates/ (27908)  
 35 biphosph?nate\$.mp. (511)  
 36 bisphosph?nate\$.mp. (17165)  
 37 diphosphonate\$.mp. (20395)  
 38 diphosphanate\$.mp. (10)  
 39 exp Etidronic Acid/ (2785)  
 40 etidronate\$.mp. (1290)  
 41 exp Clodronic Acid/ (1719)  
 42 clodronate\$.mp. (2222)  
 43 pamidronate\$.mp. (3008)  
 44 exp Alendronate/ (3988)  
 45 alendronate\$.mp. (5373)  
 46 risedronate\$.mp. (1636)  
 47 tiludronate\$.mp. (142)  
 48 ibandronate\$.mp. (964)  
 49 zoledronate\$.mp. (1335)  
 50 incadronate\$.mp. (75)  
 51 olpadronate\$.mp. (57)  
 52 neridronate\$.mp. (104)  
 53 RANK Ligand/ (8561)  
 54 RANK ligand.mp. (8879)  
 55 RANK ligand inhibitor\$.mp. (47)  
 56 denosumab.mp. (3286)  
 57 prolia.mp. (49)  
 58 Xgeva.mp. (17)  
 59 or/34-58 (45260)  
 60 exp Calcitonin/ (16174)  
 61 calcitonin.mp. (33907)  
 62 exp Denosumab/ (2225)  
 63 Adrenocorticotrophic Hormone/ (49545)  
 64 exp Adrenal Cortex Hormones/ (420169)  
 65 exp Steroids/ (909931)  
 66 (prednisone\$ or prednisolon\$ or dexamethasone\$ or corticosteroid\$).mp. (254123)  
 67 exp Calcimimetic Agents/ (1183)  
 68 cinacalcet.mp. (1371)  
 69 exp Diuretics/ (82814)  
 70 diuretic\*.mp. (54291)  
 71 exp Gallium/ (10140)  
 72 (gallium adj5 nitrate).mp. (381)  
 73 hyperhydrat\*.mp. (690)  
 74 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 (1215431)  
 75 59 or 74 (1252036)  
 76 18 and 75 (1224)  
 77 33 or 76 (1354)

Ovid MEDLINE(R) Epub Ahead of Print <December 27, 2022>, Ovid MEDLINE(R) Daily Update <December 27, 2022>

1 (cancer\* or carcinoma\* or adenocarcinoma\* or hepatocarcinoma\* or carcinosarcoma\* or sarcoma\* or histiocytoma\* or fibrosarcoma\* or osteosarcoma\* or chondrosarcoma\* or lymphosarcoma\* or rhabdomyosarcoma\* or leuk?emi\* or erythroleukem\* or erythroleukaem\* or lymphoma\* or melanoma\* or hodgkin\* or "multiple myeloma" or mesothelioma\* or neoplas\* or malignan\* or metastas\* or carcinoid\* or neuroblastoma\* or (Mycosis adj Fungoid?s) or (Sezary adj Syndrome) or Retinoblastoma\* or pheochromocytoma\* or nephroblastoma\* or choriocarcinoma\* or (Pleuropulmonary adj Blastoma?) or glioblastoma\* or glioma\* or astrocytoma\* or ependymoma\* or

medulloblastoma\* or meningioma\* or craniopharyngioma\* or myelodysplastic or myeloproliferative or macroglobulinemi\* or macroglobulinaemi\* or pineoblastoma\* or oncol\* or cyst or tumor?r\*).mp. or exp Neoplasm/ (53467)

- 2 Calcinosis/ or hypercalcemia/ or (calcinosis or hypercalcemia\*).mp. (211)
- 3 (HHM or LOH).mp. (49)
- 4 1 and 2 (98)
- 5 3 or 4 (146)
- 6 randomized controlled trial.pt. (994)
- 7 controlled clinical trial.pt. (16)
- 8 randomized.ab. (10256)
- 9 placebo.ab. (2672)
- 10 clinical trials as topic.sh. (62)
- 11 randomly.ab. (5247)
- 12 trial.ti. (5137)
- 13 6 or 7 or 8 or 9 or 10 or 11 or 12 (17489)
- 14 exp animals/ not humans.sh. (4124)
- 15 13 not 14 (17300)
- 16 meta-analysis.mp,pt. or review.pt. or search:.tw. (62904)
- 17 15 or 16 (76292)
- 18 5 and 17 (46)
- 19 Palliative Care/ (74)
- 20 "Hospice and Palliative Care Nursing"/ (13)
- 21 exp Palliative Medicine/ (1)
- 22 exp Terminal Care/ (50)
- 23 Terminally Ill/ (0)
- 24 palliat\*.mp. (1963)
- 25 ((terminal\* or advance\*) adj6 (care or caring or ill\* or sick\* or stage\*)).mp. (2074)
- 26 (terminal-stage\* or (terminal adj1 stage\*) or dying or (close adj6 death)).mp. (750)
- 27 (end adj3 life).mp. (1029)
- 28 hospice\*.mp. (466)
- 29 ((end-stage\* or (end adj1 stage\*)) adj6 (disease\* or ill\* or care or caring)).mp. (973)
- 30 ((incurable or advanced) adj6 (ill\* or disease\*)).mp. (1033)
- 31 (reduced adj1 life adj2 expectanc\*).mp. (32)
- 32 or/19-31 (6207)
- 33 18 and 32 (4)
- 34 exp Diphosphonates/ (23)
- 35 biphosph?nate\$.mp. (1)
- 36 bisphosph?nate\$.mp. (224)
- 37 diphosphonate\$.mp. (51)
- 38 diphosphanate\$.mp. (0)
- 39 exp Etidronic Acid/ (0)
- 40 etidronate\$.mp. (6)
- 41 exp Clodronic Acid/ (1)
- 42 clodronate\$.mp. (15)
- 43 pamidronate\$.mp. (26)
- 44 exp Alendronate/ (1)
- 45 alendronate\$.mp. (42)
- 46 risedronate\$.mp. (9)
- 47 tiludronate\$.mp. (1)
- 48 ibandronate\$.mp. (5)
- 49 zoledronate\$.mp. (27)
- 50 incadronate\$.mp. (0)
- 51 olpadronate\$.mp. (0)
- 52 neridronate\$.mp. (0)
- 53 RANK Ligand/ (5)
- 54 RANK ligand.mp. (17)
- 55 RANK ligand inhibitor\$.mp. (1)
- 56 denosumab.mp. (107)

- 57 prolia.mp. (4)  
58 Xgeva.mp. (3)  
59 or/34-58 (381)  
60 exp Calcitonin/ (3)  
61 calcitonin.mp. (164)  
62 exp Denosumab/ (5)  
63 Adrenocorticotrophic Hormone/ (14)  
64 exp Adrenal Cortex Hormones/ (240)  
65 exp Steroids/ (699)  
66 (prednisone\$ or prednisolon\$ or dexamethasone\$ or corticosteroid\$).mp. (2602)  
67 exp Calcimimetic Agents/ (1)  
68 cinacalcet.mp. (17)  
69 exp Diuretics/ (46)  
70 diuretic\*.mp. (370)  
71 exp Gallium/ (26)  
72 (gallium adj5 nitrate).mp. (1)  
73 hyperhydrat\*.mp. (5)  
74 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 (3838)  
75 59 or 74 (4181)  
76 18 and 75 (16)  
77 33 or 76 (18)

#### Embase

#1.	'neoplasm'/exp	5841794
#2.	cancer*:ti,ab OR carcinoma*:ti,ab OR adenocarcinoma*:ti,ab OR hepatocarcinoma*:ti,ab OR carcinosarcoma*:ti,ab OR sarcoma*:ti,ab OR histiocytoma*:ti,ab OR fibrosarcoma*:ti,ab OR osteosarcoma*:ti,ab OR chondrosarcoma*:ti,ab OR lymphosarcoma*:ti,ab OR rhabdomyosarcoma*:ti,ab OR leuk?emi*:ti,ab OR erythroleukem*:ti,ab OR erythroleukaem*:ti,ab OR lymphoma*:ti,ab OR melanoma*:ti,ab OR hodgkin*:ti,ab OR 'multiple myeloma':ti,ab OR mesothelioma*:ti,ab OR neoplas*:ti,ab OR malignan*:ti,ab OR metastas*:ti,ab OR carcinoid*:ti,ab OR neuroblastoma*:ti,ab OR fungoid?s):ti,ab) OR ((sezary NEAR/1 ((mycosis NEAR/1 syndrome):ti,ab) OR retinoblastoma*:ti,ab OR pheochromocytoma*:ti,ab OR nephroblastoma*:ti,ab OR choriocarcinoma*:ti,ab OR ((pleuropulmonary NEAR/1 blastoma?):ti,ab) OR glioblastoma*:ti,ab OR glioma*:ti,ab OR astrocytoma*:ti,ab OR ependymoma*:ti,ab OR medulloblastoma*:ti,ab OR meningioma*:ti,ab OR craniopharyngioma*:ti,ab OR myelodysplastic:ti,ab OR myeloproliferative:ti,ab OR macroglobulinemi*:ti,ab OR macroglobulinaemi*:ti,ab OR pineoblastoma*:ti,ab OR oncol*:ti,ab OR cyst:ti,ab OR tumo?r*:ti,ab	5289577
#3.	#1 OR #2	6788140
#4.	'calcinosis'/exp	21426
#5.	'hypercalcemia'/exp	32785
#6.	calcinos?s:ti,ab OR hypercalcemi*:ti,ab	27354
#7.	#4 OR #5 OR #6	60939
#8.	#3 AND #7	26855
#9.	hhm:ti,ab OR loh:ti,ab	10582
#10.	#8 OR #9	37147
#11.	'palliative therapy'/exp	136373

#12.	'terminal care'/exp	82812
#13.	'terminally ill patient'/exp	9415
#14.	palliat*:ti,ab	141744
#15.	(terminal* NEAR/6 (care OR caring OR ill*)):ti,ab	14398
#16.	(end NEAR/3 life):ti,ab	44394
#17.	hospice*:ti,ab	25736
#18.	'terminal stage*':ti,ab	4740
#19.	dying:ti,ab	51929
#20.	(close NEAR/6 death):ti,ab	1592
#21.	((incurable OR advanced) NEAR/6 (ill* OR disease*)):ti,ab	109454
#22.	#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	410948
#23.	#10 AND #22	1371
#24.	'bisphosphonic acid derivative'/exp	75381
#25.	biphosph?nate*:ti,ab	1054
#26.	bisphosph?nate*:ti,ab	28893
#27.	diphosponate*:ti,ab	4601
#28.	diphosphanate*:ti,ab	20
#29.	etidronate*:ti,ab	1604
#30.	clodronate*:ti,ab	3530
#31.	pamidronate*:ti,ab	3894
#32.	alendronate*:ti,ab	8026
#33.	risedronate*:ti,ab	3007
#34.	tiludronate*:ti,ab	187
#35.	ibandronate*:ti,ab	1991
#36.	zoledronate*:ti,ab	2459
#37.	incadronate*:ti,ab	90
#38.	olpadronate*:ti,ab	75
#39.	neridronate*:ti,ab	189
#40.	'osteoclast differentiation factor'/exp	22315
#41.	(rank NEAR/1 ligand):ti,ab	1604
#42.	denosumab:ti,ab	7094

#43.	prolia:ti,ab	126
#44.	xgeva:ti,ab	64
#45.	'calcitonin'/exp	28584
#46.	'denosumab'/exp	11986
#47.	calcitonin:ti,ab	34196
#48.	'corticotropin'/exp	77337
#49.	'corticosteroid'/exp	1142286
#50.	'steroid'/exp	1848482
#51.	prednisone*:ti,ab OR prednisolon*:ti,ab OR dexamethasone*:ti,ab OR corticosteroid*:ti,ab	349171
#52.	'calcimimetic agent'/exp	4723
#53.	cinacalcet:ti,ab	2416
#54.	'diuretic agent'/exp	456288
#55.	diuretic*:ti,ab	63923
#56.	'gallium'/exp	8628
#57.	(gallium NEAR/5 nitrate):ti,ab	396
#58.	'hyperhydration'/exp	62
#59.	hyperhydrat*:ti,ab	1196
#60.	#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59	2429812
#61.	#10 AND #60	10422
#62.	(#23 OR #61) AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND ([embase]/lim OR [pubmed-not-medline]/lim)	357

### Cochrane Library

#1 MeSH descriptor: [Neoplasms] explode all trees 90536

#2 (cancer\* or carcinoma\* or adenocarcinoma\* or hepatocarcinoma\* or carcinosarcoma\* or sarcoma\* or histiocytoma\* or fibrosarcoma\* or osteosarcoma\* or chondrosarcoma\* or lymphosarcoma\* or rhabdomyosarcoma\* or leuk?emi\* or erythroleukem\* or erythroleukaem\* or lymphoma\* or melanoma\* or hodgkin\* or "multiple myeloma" or mesothelioma\* or neoplas\* or malignan\* or metastas\* or carcinoid\* or neuroblastoma\* or (Mycosis NEAR Fungoid?s) or (Sezary NEAR Syndrome) or Retinoblastoma\* or pheochromocytoma\* or nephroblastoma\* or choriocarcinoma\* or (Pleuropulmonary NEAR Blastoma?) or glioblastoma\* or glioma\* or astrocytoma\* or ependymoma\* or medulloblastoma\* or meningioma\* or craniopharyngioma\* or myelodysplastic or myeloproliferative or macroglobulinemi\* or macroglobulinaemi\* or pineoblastoma\* or oncol\* or cyst or tumo?r\*):ti,ab 256473

#3	#1 OR #2	267599	
#4	MeSH descriptor: [Calcinosis] explode all trees	569	
#5	MeSH descriptor: [Hypercalcemia] explode all trees	224	
#6	(calcinosis or hypercalcemi*):ti,ab	1025	
#7	#4 OR #5 OR #6	1671	
#8	#3 AND #7	431	
#9	(HBM or LOH):ti,ab	223	
#10	#8 OR #9	651	

Tabel 3. Resultaten van zoekactie van onderzoeksvraag 2

Database	Aantal
Medline	1354
PreMedline	18
Embase	357
CDSR	8
CENTRAL	643
<b>Totaal aantal resultaten</b>	<b>2380</b>
Aantal geëxcludeerd (dubbelen en foute taal)	563
<b>Totaal aantal unieke resultaten</b>	<b>1817</b>

Tabel 4. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 2

Referentie	Reden voor exclusie
Ahmad, S., G. Kuraganti, and D. Steenkamp, Hypercalcemic crisis: A clinical review. American Journal of Medicine, 2015. 128(3): p. 239-245.	Narrative review
Amadori, D., et al., Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology, 2013. 14(7): p. 663-670.	Hypercalciëmie was exclusiecriteria
Anonymous, Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Reviews, 2016. 11: p. 11.	Focus is behandeling van botmetastasen
Anonymous, National Institute for Health and Care Excellence, 2019. 05: p. 05.	Focus is behandeling van botmetastasen
Asonitis, N., et al., Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature. Hormone & Metabolic Research, 2019. 51(12): p. 770-778.	Geen kwaliteitsbeoordeling van geïnccludeerde studies

Berenson, J.R., et al., American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2002. 20(17): p. 3719-3736.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Berenson, J.R., et al., Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. <i>New England Journal of Medicine</i> , 1996. 334(8): p. 488-493.	Hypercalciëmie was exclusiecriteria
Berenson, J.R., et al., Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. <i>Journal of Clinical Oncology</i> , 1998. 16(2): p. 593-602.	Hypercalciëmie was exclusiecriteria
Berenson, J.R., et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study. <i>Cancer</i> , 2001. 91(7): p. 1191-1200.	Hypercalciëmie was exclusiecriteria
Bertheault-Cvitkovic, F., et al. Randomized, double-blind comparison of pamidronate vs. gallium nitrate for acute control of cancer-related hypercalcemia. <i>Ann-oncol</i> , 1996. 7, 140.	Abstract
Bertheault, C.F., et al. Gallium nitrate (GN) vs pamidronate (APD) for acute control of cancer-related hypercalcemia (CRH): interim results of a randomized, double-blind, multi-national study. <i>Proceedings of the american society of clinical oncology</i> , 1995. 14, 171, Abstract 369.	Abstract
Body, J.J., et al., Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. <i>Journal of Bone &amp; Mineral Research</i> , 1989. 4(6): p. 923-8.	Vergelijking van dosissen
Body, J.J., et al., Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. <i>Journal of Bone &amp; Mineral Research</i> , 2010. 25(3): p. 440-6.	Hypercalciëmie was geen inclusiecriteria
Bozzo, A., et al., Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis. <i>Clinical Orthopaedics &amp; Related Research</i> , 2021. 479(9): p. 2047-2057.	Focus is behandeling van botmetastasen
Brincker, H., et al., Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. <i>British Journal of Haematology</i> , 1998. 101(2): p. 280-286.	Hypercalciëmie was geen inclusiecriteria
Carteni, G., et al., Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. <i>Oncologist</i> , 2006. 11(7): p. 841-8.	Hypercalciëmie was geen inclusiecriteria
Charles, P., C. Hasling, and L. Mosekilde Etidronate disodium for hypercalcemia of malignancy. <i>Proceedings of the american society of clinical oncology</i> , 1986. 5, 40, Abstract 155.	Abstract
Chevallier, B., et al. Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial. <i>Presse medicale (Paris, France : 1983)</i> , 1988. 17, 2375-2377.	Frans



Chisholm, M.A., A.L. Mulloy, and A.T. Taylor, Acute management of cancer-related hypercalcemia. <i>Annals of Pharmacotherapy</i> , 1996. 30(5): p. 507-13.	Narrative review
D'Arena, G., et al., Pamidronate versus observation in asymptomatic myeloma: Final results with long-term follow-up of a randomized study. <i>Leukemia and Lymphoma</i> , 2011. 52(5): p. 771-775.	Hypercalciëmie was exclusiecr criterium
Daragon, A., et al. Treatment of hypercalcemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Results of a stratified, double-blind, randomized two-month dose-response study. <i>Current therapeutic research - clinical and experimental</i> , 1991. 50, 10-21.	Geen full-text
Davis, J.R. and D.A. Heath, Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. <i>British Journal of Clinical Pharmacology</i> , 1989. 28(3): p. 269-74.	Vergelijking van dosissen
Delmas, P., et al. Dichloromethylene diphosphonate (Cl <sub>2</sub> MDP) treatment of hypercalcaemia produced from bone metastases (author's transl). <i>Nouvelle presse medicale</i> , 1982. 11, 1471-1474.	Frans
Dhillon, S. and K.A. Lyseng-Williamson, Zoledronic acid: A review of its use in the management of bone metastases of malignancy. <i>Drugs</i> , 2008. 68(4): p. 507-534.	Narrative review
Diel, I., et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. <i>European journal of cancer</i> , 2011. 47, S237 DOI: 10.1016/S0959-8049%2811%2971124-8.	Abstract
Diel, I.J., et al., The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. <i>European Journal of Cancer</i> , 2015. 51(11): p. 1467-75.	Hypercalciëmie was exclusiecr criterium
Djulgovic, B., et al., Bisphosphonates in multiple myeloma. <i>Cochrane Database of Systematic Reviews</i> , 2001(4): p. CD003188.	Updated
Djulgovic, B., et al., Bisphosphonates in multiple myeloma. <i>Cochrane Database of Systematic Reviews</i> , 2002(3): p. CD003188.	Updated
Dodwell, D.J., et al., Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1992. 68(800): p. 434-9.	Vergelijking van dosissen
Fallah-Rad, N. and A.R. Morton, Managing hypercalcaemia and hypocalcaemia in cancer patients. <i>Current Opinion in Supportive &amp; Palliative Care</i> , 2013. 7(3): p. 265-71.	Narrative review
Flores, J., et al. Evaluation of 24-hour infusion of Didronel® for the treatment of hypercalcemia of malignancy. <i>Proceedings of the american society of clinical oncology</i> , 1993. 12, 435, Abstract 1499.	Abstract
Flores, J.F., et al., Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. <i>Cancer</i> , 1994. 73(10): p. 2527-34.	Geen RCT, vergelijking van dosissen

Ford, J., et al., Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. <i>Health Technology Assessment</i> , 2013. 17(29): p. 1-385.	Focus is behandeling van botmetastasen
Fujiwara, Y., et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. <i>Annals of oncology</i> , 2010. 21, ix12 DOI: 10.1093/annonc/mdq560.	Abstract
Fukumoto, S., et al. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. <i>Journal of clinical endocrinology and metabolism</i> , 1994. 79, 165-170 DOI: 10.1210/jc.79.1.165.	Vergelijking van dosissen
Garcia-Sanz, R., et al. The use of single agent zoledronic acid prevents the development of bone disease complications in myeloma patients with asymptomatic relapses with no demonstrated effect on symptoms progression. <i>Haematologica</i> , 2014. 99, 103.	Geen full-text
Guay, D.R., Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. <i>Pharmacotherapy: The Journal of Human Pharmacology &amp; Drug Therapy</i> , 2006. 26(5): p. 655-73.	Narrative review
Gucalp, R., et al. A double-blind controlled study of two infusion regimens of 60 mg pamidronate versus saline in the treatment of hypercalcemia of malignancy. <i>Proceedings of the american society of clinical oncology</i> , 1993. 12, 431, Abstract 1484.	Abstract
Gucalp, R., et al., Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. <i>Archives of Internal Medicine</i> , 1994. 154(17): p. 1935-44.	Vergelijking van dosissen
Hasling, C., P. Charles, and L. Mosekilde, Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study. <i>European Journal of Clinical Investigation</i> , 1986. 16(5): p. 433-7.	Zelfde studie als Hasling 1987
Heim, M.E., et al., Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. <i>Onkologie</i> , 1995. 18(5): p. 439-448.	Geen full-text
Hillner, B.E., et al., American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. <i>Journal of Clinical Oncology</i> , 2000. 18(6): p. 1378-91.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Horiuchi, K., et al., Hypercalcemia following discontinuation of denosumab therapy: A systematic review. <i>Bone Reports</i> , 2021. 15.	Gaat niet over behandeling van hypercalciëmie
Hortobagyi, G.N., et al., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. <i>New England Journal of Medicine</i> , 1996. 335(24): p. 1785-1791.	Hypercalciëmie was exclusie criterium

Hu, Z., et al., The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Supportive Care in Cancer</i> , 2020. 28(7): p. 3291-3301.	Gaat niet over behandeling van hypercalciëmie
Hughes, T.E. and L.A. Hansen, Gallium nitrate. <i>Annals of Pharmacotherapy</i> , 1992. 26(3): p. 354-62.	Narrative review
Hultborn, R., et al., Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. <i>Anticancer Research</i> , 1999. 19(4C): p. 3383-92.	Hypercalciëmie was geen inclusie criterium
Imrie, K., et al., Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma. <i>Current Oncology</i> , 2005. 12(1): p. 3-17.	Geen full-text
Jakob, T., et al., Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. <i>Cochrane Database of Systematic Reviews</i> , 2020. 12: p. CD013020.	Focus is behandeling van botmetastasen
James, N., et al., TRAPEZE: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016. 20(53): p. 1-127.	Hypercalciëmie was geen inclusie criterium
Jang, A., et al., Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020. 4(2): p. 93-102.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, geen RCTs over behandeling
Kanis, J.A., et al., Clodronate decreases the frequency of skeletal metastases in women with breast cancer. <i>Bone</i> , 1996. 19(6): p. 663-667.	Hypercalciëmie was geen inclusie criterium
Kawada, K., et al., A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. <i>Japanese Journal of Clinical Oncology</i> , 2005. 35(1): p. 28-33.	Geen RCT
Keith, B.D., Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. <i>BMC Cancer</i> , 2008. 8.	Gaat niet over behandeling van hypercalciëmie
Kohno, N., et al. A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. <i>Annual meeting proceedings of the american society of clinical oncology</i> , 2004. 43.	Abstract
Kraj, M., et al., Effect of pamidronate on skeletal morbidity in myelomatosis part 1. The results of the first 12 months of pamidronate therapy. <i>Acta Poloniae Pharmaceutica - Drug Research</i> , 2000. 57(SUPPL.): p. 113-116.	Geen full-text
Kraj, M., et al., The effects of 8-year pamidronate treatment on skeletal morbidity in patients with advanced multiple myeloma. <i>Nowotwory</i> , 2004. 54(6): p. 570-577.	Hypercalciëmie was geen inclusie criterium

Kristensen, B., et al., Oral clodronate in breast cancer patients with bone metastases: A randomized study. <i>Journal of Internal Medicine</i> , 1999. 246(1): p. 67-74.	Hypercalciëmie was exclusiecr criterium
Lahtinen, R., et al., Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. <i>Lancet</i> , 1992. 340(8827): p. 1049-1052.	Hypercalciëmie was geen inclusiecr criterium
Li, F., et al., An Effective Therapy to Painful Bone Metastases: Cryoablation Combined with Zoledronic Acid. <i>Pathology and Oncology Research</i> , 2014. 20(4): p. 885-891.	Hypercalciëmie was geen inclusiecr criterium
Lipton, A., et al. Prevention of skeletal-related events with denosumab or zoledronic acid - Combined analysis from 3 registrational trials. <i>European journal of cancer</i> , 2011. 47, S240 DOI: 10.1016/S0959-8049%2811%2971134-0.	Abstract
Lipton, A., et al., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. <i>Cancer</i> , 2000. 88(5): p. 1082-1090.	Hypercalciëmie was exclusiecr criterium
Machado, M., et al., Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials. <i>Clinical Therapeutics</i> , 2009. 31(5): p. 962-979.	Focus is behandeling van botmetastasen
Macherey, S., et al., Bisphosphonates for advanced prostate cancer. <i>Cochrane Database of Systematic Reviews</i> , 2017. 12: p. CD006250.	Focus is behandeling van botmetastasen
Major, P., et al. Zoledronic acid is superior to Pamidronate in the treatment of tumor-induced hypercalcemia: a pooled analysis. <i>Proceedings of the american society of clinical oncology</i> , 2000. 19, 605a, Abstract 2382.	Abstract
Major, P., The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. <i>Oncologist</i> , 2002. 7(6): p. 481-91.	Narrative review
Major, P.P. and R.E. Coleman, Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. <i>Seminars in Oncology</i> , 2001. 28(2 Suppl 6): p. 17-24.	Zelfde resultaten als Major 2001
Martin, M., et al., Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , 2012. 18(17): p. 4841-4849.	Hypercalciëmie was geen inclusiecr criterium
Martinez-Zapata, M.J., et al., Calcitonin for metastatic bone pain. <i>Cochrane Database of Systematic Reviews</i> , 2006(3): p. CD003223.	Updated
Martinez-Zapata, M.J., et al., Calcitonin for metastatic bone pain. <i>Cochrane Database of Systematic Reviews</i> , 2009(4).	Focus is behandeling van botmetastasen
Martinez, M.J., et al., Calcitonin for metastatic bone pain. <i>Cochrane Database of Systematic Reviews</i> , 2003(3): p. CD003223.	
Matsumoto, T. Dose Finding Study of YM175 in Patients with Hypercalcemia Associated with Malignant Tumor. <i>Rinsho to kenkyu (the japanese journal of clinical and experimental medicine)</i> , 1994. 71, 3263-3280.	Geen full-text

Matsumoto, T., et al. Dose-Findings Study of Pamidronate Disodium (AHPrBP) in Patients with Tumor-Associated Hypercalcemia. <i>Rinsho iyaku (journal of clinical therapeutics and medicines)</i> , 1992. 8, 605-629.	Geen full-text
Mavrogenis, A.F., et al., Modern Palliative Treatments for Metastatic Bone Disease: Awareness of Advantages, Disadvantages, and Guidance. <i>Clinical Journal of Pain</i> , 2016. 32(4): p. 337-50.	Narrative review
McCloskey, E.V., et al., A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. <i>British Journal of Haematology</i> , 1998. 100(2): p. 317-325.	Hypercalciëmie was geen inclusie criterium
McCurdy, M.T. and C.B. Shanholtz, Oncologic emergencies. <i>Critical Care Medicine</i> , 2012. 40(7): p. 2212-22.	Narrative review
Menssen, H.D., et al., Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. <i>Journal of Clinical Oncology</i> , 2002. 20(9): p. 2353-2359.	Hypercalciëmie was exclusie criterium
Messa, P., C. Alfieri, and B. Brezzi, Clinical utilization of cinacalcet in hypercalcemic conditions. <i>Expert Opinion On Drug Metabolism &amp; Toxicology</i> , 2011. 7(4): p. 517-28.	Narrative review
Mhaskar, R., et al., Bisphosphonates in multiple myeloma: a network meta-analysis. <i>Cochrane Database of Systematic Reviews</i> , 2012(5): p. CD003188.	Updated
Mhaskar, R., et al., Bisphosphonates in multiple myeloma: an updated network meta-analysis. <i>Cochrane Database of Systematic Reviews</i> , 2017. 12: p. CD003188.	Focus is behandeling van botmetastasen
Mhaskar, R., et al., Bisphosphonates in multiple myeloma. <i>Cochrane Database of Systematic Reviews</i> , 2010(3): p. CD003188.	
Morgan, G., et al. Effects of zoledronic acid (ZOL) versus clodronate (CLO) on myeloma-related organ or tissue impairment (ROTI) in patients with multiple myeloma (MM) in the MRC myeloma IX study. <i>Haematologica</i> , 2011. 96, 217.	Geen full-text
Morgan, G.J., et al., Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. <i>The Lancet Oncology</i> , 2011. 12(8): p. 743-752.	Hypercalciëmie was geen inclusie criterium
Morton, A.R., et al., Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. <i>British Medical Journal Clinical Research Ed.</i> , 1988. 296(6625): p. 811-4.	Vergelijking van dosissen
Mundy, G.R., R. Wilkinson, and D.A. Heath, Comparative study of available medical therapy for hypercalcemia of malignancy. <i>American Journal of Medicine</i> , 1983. 74(3): p. 421-32.	Mix van patiënten met kanker of primaire hypoparathyreoïdie
Musto, P., et al., Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. <i>Leukemia &amp; Lymphoma</i> , 2003. 44(9): p. 1545-8.	Hypercalciëmie was exclusie criterium

Neskovic-Konstantinovic, Z., et al., Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. Supportive Care in Cancer, 1995. 3(6): p. 422-4.	Geen RCT
Nussbaum, S., et al. Treatment of cancer - associated hypercalcemia with Alendronate (Aminohydroxybutylidene bisphosphonate). Proceedings of the american society of clinical oncology, 1992. 11, 377, Abstract 1306.	Abstract
Nussbaum, S.R., et al., Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Journal of Clinical Oncology, 1993. 11(8): p. 1618-23.	Vergelijking van dosissen
Nussbaum, S.R., et al., Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. American Journal of Medicine, 1993. 95(3): p. 297-304.	Vergelijking van dosissen
O'Carrigan, B., et al., Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2017. 2017(10).	Focus is behandeling van botmetastasen
Palmieri, C., J.R. Fullarton, and J. Brown, Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: A mixed-treatment meta-analysis. Clinical Cancer Research, 2013. 19(24): p. 6863-6872.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, enkel gezocht in PubMed
Paterson, A., et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - Final analysis. Cancer research, 2011. 71, DOI: 10.1158/0008-5472.SABCS11-S2-3.	Abstract
Pecherstorfer, M., E. Steinhauer, and S. Pawsey Ibandronic acid is more effective than pamidronate in lowering serumcalcium in patients with severe hypercalcemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calcium levels. Results of a randomised, open label, comparative study. Proceedings of the american society of clinical oncology, 2001. 20 (Pt 1), 385a, Abstract 1535.	Abstract
Pecherstorfer, M., et al. A randomized study of ibandronate and pamidronate in hypercalcemia of malignancy (HCM). Ibandronate is more effective in the subset of patients with severe HCM and has at least equal efficacy to pamidronate in HCM patients with less elevated baseline calcium levels. European journal of cancer, 2001. 37, S171.	Abstract
Pecherstorfer, M., et al., Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of Clinical Oncology, 1996. 14(1): p. 268-76.	Vergelijking van dosissen
Peck, W.A., Results of a randomized study of clodronate in treating cancer-related hypercalcemia. Archives of Internal Medicine, 1987. 147(11): p. 2056-7.	Letter
Per A randomized, double-blind, multicentric study of zoledronic acid (4 mg and 8 mg) administered intravenously to patients with recidival or refractory hypercalcemia, induced by neoplasia. <a href="http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-062-02">http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-062-02</a> , 2002.	Trial protocol

Perry, C.M. and D.P. Figgitt, Zoledronic acid: a review of its use in patients with advanced cancer. <i>Drugs</i> , 2004. 64(11): p. 1197-211.	Narrative review
Pi, J., et al., A review in the treatment of oncologic emergencies. <i>Journal of Oncology Pharmacy Practice</i> , 2016. 22(4): p. 625-38.	Narrative review
Qasim, S., et al. Therapeutic efficacy and Pharmacoeconomics evaluation of pamidronate versus zoledronic acid in multiple myeloma patients. <i>Journal of applied pharmacy</i> , 2011. 3, 438-452.	Geen full-text
Raje, N., et al., Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. <i>Blood Cancer Journal</i> , 2016. 6.	Hypercalciëmie was geen inclusie criterium
Ralston, S.H., et al., Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. <i>British Journal of Cancer</i> , 1997. 75(2): p. 295-300.	Vergelijking van dosissen
Ritch, P.S., et al. Double-blind evaluation of intravenous etidronate for cancer-related hypercalcemia. <i>Proceedings of the american society of clinical oncology</i> , 1987. 6, 265, Abstract 1042.	Abstract
Rizzoli, R., et al., Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. <i>Bone</i> , 1996. 18(6): p. 531-7.	Hypercalciëmie was geen inclusie criterium
Rizzoli, R., et al., Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> , 1999. 84(10): p. 3545-50.	Posthoc analyse van twee RCTs
Roqué i Figuls, M., et al., Radioisotopes for metastatic bone pain. <i>Cochrane Database of Systematic Reviews</i> , 2011. 2011(7).	Updated
Roque, I.F.M., et al., WITHDRAWN: Radioisotopes for metastatic bone pain. <i>Cochrane Database of Systematic Reviews</i> , 2017. 3: p. CD003347.	Focus is behandeling van botmetastasen
Rosen, L.S., et al., Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. <i>Cancer</i> , 2003. 98(8): p. 1735-44.	Hypercalciëmie was exclusie criterium
Rosen, L.S., et al., Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. <i>Cancer</i> , 2004. 100(12): p. 2613-21.	Hypercalciëmie was geen inclusie criterium
Rosen, L.S., et al., Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group. <i>Journal of Clinical Oncology</i> , 2003. 21(16): p. 3150-3157.	Hypercalciëmie was geen inclusie criterium
Sacco, E., et al., Paraneoplastic syndromes in patients with urological malignancies. <i>Urologia Internationalis</i> , 2009. 83(1): p. 1-11.	Geen kwaliteitsbeoordeling van geïnccludeerde

	studies, enkel gezocht in Medline
Sato, K., et al. Comparative Clinical Study of Alendronate with Eel Calcitonin in Hypercalcemia of Malignancy. <i>Rinsho iyaku (journal of clinical therapeutics and medicines)</i> , 1994. 10, 2667-2689.	Geen full-text
Sauter, N., et al. Analysis of skeletal morbidity in breast cancer (BC) patients treated with zoledronic acid (Zol) or placebo: time to first pathologic fracture. <i>Journal of clinical oncology: ASCO annual meeting proceedings</i> , 2006. 24, 10639.	Abstract
Sawyer, N., et al., Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (ADP)) as single shot treatment of hypercalcaemia. <i>Bone and Mineral</i> , 1990. 9(2): p. 121-128.	Vergelijking van dosissen
Saylor, P.J., et al., New and emerging therapies for bone metastases in genitourinary cancers. <i>European Urology</i> , 2013. 63(2): p. 309-20.	Narrative review
Shah, S., et al., Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? <i>British Journal of Cancer</i> , 2002. 86(8): p. 1235-7.	Vergelijking van dosissen
Shevrin, D., et al. Combination therapy for cancer-associated hypercalcemia with mithramycin and oral etidronate. <i>Proceedings of the american society of clinical oncology</i> , 1984. 3, 92, Abstract C-357.	Abstract
Silverberg, S.J., et al., Cinacalcet hydrochloride reduces the serumcalcium concentration in inoperable parathyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007. 92(10): p. 3803-3808.	Geen RCT
Sleeboom, H.P., et al., Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. <i>Lancet</i> , 1983. 2(8344): p. 239-43.	Geen RCT
Small, E.J., et al., Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2003. 21(23): p. 4277-84.	Hypercalciëmie was exclusie criterium
Steinhauer, E., et al. Ibandronate (BM 21.0955) is effective in normalizing serumcalcium in malignant hypercalcemia (HC). <i>Proceedings of the american society of clinical oncology</i> , 1995. 14, 530, Abstract 1747.	Abstract
Stopeck, A., et al. A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases. 2010. 69, DOI: 10.1158/0008-5472.SABCS-09-22.	Abstract
Theriault, R.L., et al., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 1999. 17(3): p. 846-854.	Hypercalciëmie was exclusie criterium
Thiébaud, D., et al. Treatment of neoplastic hypercalcemia using single-infusion diphosphonate. <i>Schweizerische medizinische Wochenschrift</i> , 1988. 118, 77-81.	Frans



Tubiana-Hulin, M., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. <i>Bulletin du cancer</i> , 2001. 88, 701-707.	Frans
Wang, X., et al., Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. <i>Oncology Letters</i> , 2014. 7(6): p. 1997-2002.	Focus is behandeling van botmetastasen
Wang, Y., et al., Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013. 14(3): p. 254-60.	Hypercalciëmie was exclusie criterium
Warrell, R., et al. Treatment of cancer associated hypercalcemia with alendronate sodium: a randomized double-blind comparison with etidronate. <i>Proceedings of the American Society of Clinical Oncology</i> , 1993. 12, 438, Abstract 1514.	Abstract
Warrell, R.P., Jr., et al., Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. <i>Cancer Research</i> , 1986. 46(8): p. 4208-12.	Geen RCT
Wellington, K. and K.L. Goa, Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. <i>Drugs</i> , 2003. 63(4): p. 417-37.	Narrative review
Wimalawansa, S.J., Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. <i>Clinical Endocrinology</i> , 1994. 41(5): p. 591-5.	Vergelijking van verschillende frequenties van toediening
Witte, R.S., et al., Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. <i>Archives of Internal Medicine</i> , 1987. 147(5): p. 937-9.	Geen full-text
Wong, R. and P.J. Wiffen, Bisphosphonates for the relief of pain secondary to bone metastases. <i>Cochrane Database of Systematic Reviews</i> , 2002(2): p. CD002068.	Updated
Wong, R.K.S. and P.J. Wiffen, Bisphosphonates for the relief of pain secondary to bone metastases. <i>Cochrane Database of Systematic Reviews</i> , 2009(4).	Focus is behandeling van botmetastasen
Wu, C., H. Jiang, and J. Chen, A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer. <i>Current Medicinal Chemistry - Anti-Cancer Agents</i> , 2020. 20(13): p. 1604-1612.	Geen full-text
Wu, S., W.L. Dahut, and J.L. Gulley, The use of bisphosphonates in cancer patients. <i>Acta Oncologica</i> , 2007. 46(5): p. 581-591.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, enkel gezocht in Medline
Yang, M. and X. Yu, Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. <i>Supportive Care in Cancer</i> , 2020. 28(6): p. 2533-2540.	Focus is behandeling van botmetastasen

Zaghloul, M.S., et al., A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. <i>International Journal of Clinical Oncology</i> , 2010. 15(4): p. 382-9.	Hypercalciëmie was exclusie criterium
Zheng, G.Z., et al., Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. <i>European Journal of Cancer Care</i> , 2017. 26(6).	Gaat niet over behandeling van hypercalciëmie
Zysset, E., et al., Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. <i>Bone &amp; Mineral</i> , 1992. 18(3): p. 237-49.	Vergelijking van dosissen

Bijlage GRADE profielen  
(per onderzoeksvraag op te stellen; export vanuit GRADEpro)